Science: Biology

20 Companies That Have Worked Out Molecular Diagnostic Deals Recently

Leave a comment



ARLINGTON, Va. (PRWEB)

According to Kalorama Information’s The World Market for Molecular Diagnostics Tests, 11th Edition, the demand for molecular in vitro diagnostics (IVD) means that very often a single firm cannot go it alone and must find partners.

These are partnerships involving 20 companies that have just occurred in recent months:

  • Qiagen Neuron23 an agreement to develop a NGS based companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease; planned to be developed using the NextSeq 500 System

  • AstraZeneca and Biocartis: development of a novel companion diagnostic test on Biocartis’ molecular Idylla platform, for use with Tagrisso (osimertinib), AstraZeneca’s third-generation EGFR-TKI (tyrosine kinase inhibitor) treatment”

  • Cepheid BioGX: collaboration to deliver a PCR test for monkeypox that will run on the GeneXpert system

  • Exact Sciences Ultima Genomics: Ultima Genomics will provide access to its NGS products, which are based on a new architecture designed to enable sequencing at a fraction of the cost of other technologies; develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology; Exact Sciences investing in Ultima

  • Immucor and Pirche: a multi-year partnership to expand Immucor’s transplant diagnostics software; Immucor makes investment in Pirche; goal to provide users a seamless and direct interface with the Pirche epitope matching prediction pipeline in their transplant analysis software

  • QuantuMDx and Sansure Biotech global R&D, manufacturing and commercial partnership aimed to bring a comprehensive array of molecular diagnostic assays to the Q-POC platform; Sansure gets exclusive rights to Q-POC in China, for which QuantuMDx receives licensing and royalty payments; QuantuMDx will have the exclusive rights to sell Sansure-translated assays outside China

  • Bio-Rad and Curiosity Diagnostics acquiring Curiosity for total consideration of up to $170 M, consisting of approximately $100 M in cash, and up to $70 M in future milestone payments

  • Roche and Amoy Diagnostics: strategic partnership; jointly promote the development of an open, cooperative and innovative medical and health ecosystem and provide patients with more accurate digital medical solutions

  • Bio-Rad and 10x Genomics: companies agree to global patent cross-licensing for patents held by Bio-Rad and 10x Genomics, resolving outstanding legal issues in the field of single-cell genomics; non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis

  • Meridian Bioscience and SD Biosensor and SJL Partners: definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.


About Kalorama Information:

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Leave a Reply